Histamine glutarimide

Drug Profile

Histamine glutarimide

Alternative Names: XC-8

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EURRUS BIOTECH
  • Class Antiasthmatics; Antibronchitics; Biogenic amines; Peptides
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma

Most Recent Events

  • 07 Sep 2017 Immunogenicity and adverse events data from preclinical studies in Asthma released by EURRUS Biotech
  • 01 May 2017 EURRUS Biotech completes a phase I trial in Asthma (In volunteers) in Austria, Germany (NCT02882217)
  • 01 Aug 2016 Phase-I clinical trials in Asthma (In volunteers) in Austria, Germany (PO) (NCT02882217)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top